Engimmune Therapeutics develops off-the-shelf soluble T-cell receptor (TCR) drugs using proprietary AI-guided protein engineering to enhance target affinity and stability for treating solid tumors. The company addresses the challenge of limited treatment options for solid tumors and immune-mediated diseases by rapidly identifying and engineering multi-specific TCRs for potent immune responses.
Funding
$16.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current treatment options for solid tumors and immune-mediated diseases are limited. Traditional approaches often struggle to elicit potent and durable immune responses against solid tumors due to challenges in target affinity, stability, and safety.
Solution
Engimmune Therapeutics is developing off-the-shelf soluble T-cell receptor (TCR) drugs for treating solid tumor cancers. The company's proprietary AI-guided protein engineering platforms rapidly identify and engineer multi-specific soluble TCRs. These TCRs are designed for high target affinity, enhanced stability, and improved safety profiles, triggering potent and durable immune cell responses against solid tumors. This approach aims to overcome challenges associated with soluble TCR development, unlocking new targets for transformative treatments in oncology and autoimmune indications.
Target Audience
The primary target audience includes patients with solid tumor cancers and immune-mediated diseases, as well as healthcare providers seeking more effective and safer treatment options.
Features
- AI-guided protein engineering platform for rapid TCR identification and engineering
- Multi-specific soluble TCRs designed for high target affinity
- Enhanced TCR stability for improved therapeutic efficacy
- Improved safety profiles compared to traditional TCR therapies
- Pipeline of novel and fast-follower programs targeting underserved oncology and autoimmune indications
- Lead asset currently in preclinical development